혈액 스크리닝 시장 예측(2026-2032년)

The Blood Screening Market is projected to grow by USD 6.50 billion at a CAGR of 9.07% by 2032.

Blood Screening Executive Summary

Blood screening is a critical pillar of transfusion safety, infectious disease surveillance, prenatal care, oncology support, organ transplantation, and population health programs. The field spans serological testing, nucleic acid testing, immunohematology, hematology screening, molecular diagnostics, pathogen reduction support, and donor eligibility assessment. Demand is shaped by the continuing need to prevent transfusion-transmitted infections, improve early disease detection, strengthen blood bank quality systems, and support resilient healthcare infrastructure. Key industry priorities include faster turnaround time, higher analytical sensitivity, automation of high-volume workflows, standardized quality control, and compliance with evolving regulatory and accreditation requirements. Blood screening programs are also increasingly linked to digital health records, laboratory information systems, donor management platforms, and public health reporting networks, creating a more connected ecosystem for traceability, hemovigilance, and risk-based decision-making. Public health guidance from global and national authorities consistently identifies safe, quality-assured blood and blood components as essential to healthcare delivery, reinforcing the strategic importance of reliable blood screening across hospitals, blood centers, and diagnostic laboratories.

Transformative Shifts in the Blood Screening Landscape

The blood screening landscape is undergoing a structural shift from reactive testing toward integrated, risk-based, and digitally enabled screening models. Laboratories and blood centers are adopting automated analyzers, sample-to-answer molecular platforms, multiplex assays, and enhanced data management systems to reduce manual variation and improve operational consistency. Regulatory expectations around donor safety, pathogen surveillance, documentation, and quality assurance continue to encourage standardized testing algorithms and robust validation practices. At the same time, emerging and re-emerging infectious threats, including arboviruses and respiratory pathogens with public health implications, have reinforced the importance of adaptable screening programs that can incorporate new assays when epidemiological risks change. Healthcare systems are also prioritizing decentralized sample collection, improved cold chain coordination, barcode-enabled traceability, and interoperability between laboratory and clinical systems. These shifts are making blood screening more predictive, scalable, and responsive to both routine healthcare needs and public health emergencies, while maintaining the central requirement for evidence-based validation and trained laboratory oversight.

Cumulative Impact of Artificial Intelligence on Blood Screening

Artificial intelligence is beginning to influence blood screening through workflow optimization, image interpretation, anomaly detection, predictive donor risk assessment, and laboratory quality management. AI-enabled decision support can help prioritize samples, identify testing bottlenecks, flag inconsistent results, and support more efficient resource allocation in high-throughput environments. In hematology and morphology workflows, machine learning tools can assist with pattern recognition and triage, while advanced analytics can strengthen hemovigilance by identifying trends in adverse events, donor deferrals, and infectious marker reactivity. AI also supports predictive maintenance for laboratory instruments and can improve inventory planning by linking screening capacity with blood supply needs. However, adoption depends on validated algorithms, transparent performance metrics, cybersecurity safeguards, bias monitoring, regulatory acceptance, and human oversight. The cumulative impact of AI is therefore not the replacement of laboratory expertise, but the augmentation of screening accuracy, traceability, turnaround time, and operational resilience across blood banks, reference laboratories, and integrated healthcare networks.

Key Regional Insights for Blood Screening

Asia-Pacific is marked by diverse healthcare systems, large patient populations, expanding diagnostic infrastructure, and sustained investment in blood safety modernization. Countries across the region are strengthening voluntary blood donation systems, screening coverage, and molecular testing capabilities, while urban hospital networks increasingly rely on automation to manage rising procedure volumes. Europe benefits from harmonized safety expectations, well-established blood establishments, high levels of compliance monitoring, and strong emphasis on traceability, donor protection, and evidence-based screening protocols under regional blood and tissue safety frameworks. North America has a mature blood screening environment supported by stringent regulatory oversight, advanced laboratory automation, broad adoption of nucleic acid testing, and strong hemovigilance practices, with continued focus on donor safety, emerging pathogen readiness, digital traceability, and continuous quality improvement. Latin America is advancing blood screening through national blood services, regional quality initiatives, and improved infectious disease testing, although access and infrastructure can vary across urban and rural settings. Africa continues to prioritize expanded screening access, strengthened national blood transfusion services, infectious disease control, and donor recruitment, with international health guidance supporting improvements in testing quality, supply reliability, and laboratory capacity. The Middle East is investing in hospital modernization, centralized laboratory networks, and blood bank accreditation, with increasing attention to transfusion safety, molecular diagnostics, and integrated clinical laboratory systems.

Key Group Insights for Blood Screening

NATO member countries, many of which overlap with advanced healthcare systems, place strategic emphasis on resilient medical supply chains, interoperable health systems, secure blood availability, and emergency preparedness for civilian and defense-related health needs. G7 countries generally demonstrate high levels of laboratory automation, robust regulatory frameworks, mature donor screening protocols, quality-assured transfusion medicine practices, and strong preparedness for emerging infectious disease risks. BRICS countries present a mixed but influential landscape, combining large-scale public health needs with expanding diagnostic manufacturing, molecular testing adoption, national blood safety initiatives, and efforts to improve equitable access across diverse healthcare infrastructures. The European Union is defined by coordinated regulatory principles, cross-border safety expectations, traceability requirements, donor protection measures, and sustained investment in quality management across blood establishments. Within ASEAN, blood screening priorities are shaped by the need to harmonize quality standards across varied healthcare systems while improving access to reliable testing, voluntary donation, centralized blood service models, and laboratory workforce capability. GCC countries are emphasizing advanced hospital infrastructure, accreditation-driven laboratory practices, national digital health strategies, and blood bank modernization, supporting stronger transfusion safety and rapid adoption of automated screening technologies. Across these groups, the central themes are quality standardization, donor safety, infectious disease readiness, digital traceability, and resilient blood system performance.

Key Country Insights for Blood Screening

China is expanding blood screening capacity through hospital modernization, molecular diagnostics adoption, stronger quality controls, and continued development of centralized and regionalized blood services. The United States has one of the most advanced blood screening ecosystems, characterized by stringent donor eligibility rules, broad use of infectious disease screening, nucleic acid testing, regulatory oversight, and mature hemovigilance systems. Japan and South Korea maintain technologically advanced laboratory systems, high-quality standards, and strong adoption of automated diagnostics, while India is focused on improving screening access, voluntary donation, blood bank standardization, infectious disease testing, and quality assurance across a large and diverse healthcare network. Germany, France, Italy, and Spain operate mature European blood screening systems supported by regulatory compliance, automation, established transfusion medicine expertise, and well-developed hemovigilance practices. The United Kingdom maintains rigorous blood safety governance, centralized guidance, donor screening controls, and strong hemovigilance reporting, while Australia benefits from coordinated blood services, strict donor screening, and established quality assurance systems that support reliable transfusion safety across a geographically dispersed population. Canada emphasizes national coordination, donor safety, laboratory quality, and traceability across its blood system. Russia's blood screening environment is influenced by large geographic coverage needs, public healthcare infrastructure, and centralized safety requirements. Brazil combines a large transfusion network with ongoing infectious disease surveillance and quality improvement efforts, while Mexico is strengthening blood safety through public health initiatives, improved donor screening, and modernization of laboratory workflows.

Actionable Recommendations for Blood Screening Leaders

Industry leaders should prioritize validated automation, interoperable laboratory information systems, and risk-based screening strategies that align with evolving regulatory and public health requirements. Investment in nucleic acid testing, multiplex platforms, quality control programs, staff training, and competency assessment can strengthen accuracy and operational resilience. Blood centers and diagnostic laboratories should develop flexible assay adoption pathways to respond to emerging infectious threats and should integrate hemovigilance data into continuous improvement programs. Leaders should also enhance cybersecurity, data governance, barcode-enabled traceability, and audit readiness as screening workflows become more digital. Strategic collaboration with public health agencies, hospitals, accreditation bodies, donor recruitment organizations, and transfusion medicine experts can improve supply reliability and screening coverage. In resource-constrained settings, phased modernization, centralized reference testing, workforce development, external quality assessment participation, and standardized operating procedures can deliver measurable improvements in transfusion safety without overextending infrastructure.

Research Methodology

This executive summary is developed through a structured secondary research approach using publicly available and verifiable sources such as health authority guidance, blood safety frameworks, regulatory documents, peer-reviewed literature, transfusion medicine standards, laboratory quality guidelines, accreditation requirements, and public health publications. The analysis focuses on qualitative evidence related to technology adoption, regulatory direction, regional healthcare infrastructure, infectious disease screening practices, donor safety, laboratory automation, hemovigilance, and digital transformation. Insights are triangulated across multiple source categories to improve reliability and avoid dependence on a single information stream. The methodology excludes market sizing, revenue estimation, share analysis, or forecasting and instead emphasizes verified industry dynamics, operational trends, policy influences, and evidence-based strategic implications for blood screening stakeholders.

Conclusion

Blood screening is evolving from a core safety function into a digitally connected, intelligence-driven component of modern healthcare systems. The sector's direction is shaped by automation, molecular diagnostics, quality standardization, AI-enabled analytics, data interoperability, and preparedness for emerging infectious risks. Regional and country-level differences remain significant, particularly in infrastructure maturity, screening access, workforce capacity, and regulatory alignment, but the global trajectory is consistent: safer transfusion practices, stronger traceability, faster testing workflows, better hemovigilance, and more resilient blood systems. Industry leaders that invest in validated technology, workforce capability, interoperability, cybersecurity, and adaptive quality systems will be best positioned to support patient safety, public health readiness, and sustainable blood screening performance.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Blood Screening Market, by Offering

• 7.1. Introduction
• 7.2. Instruments
• 7.3. Reagents & Kits
• 7.4. Controls & Calibrators
• 7.5. Software & Informatics
• 7.6. Services

8. Blood Screening Market, by Test Type

• 8.1. Introduction
• 8.2. Hepatitis B Screening
• 8.3. Hepatitis C Screening
• 8.4. HIV Screening
• 8.5. Syphilis Screening

9. Blood Screening Market, by Technology

• 9.1. Introduction
• 9.2. Chemiluminescence
• 9.3. Flow Cytometry
• 9.4. Immunoassays
  • 9.4.1. Chemiluminescence Immunoassay
  • 9.4.2. Enzyme Linked Immunosorbent Assay
  • 9.4.3. Radioimmunoassay
• 9.5. Molecular Diagnostics
  • 9.5.1. Isothermal Amplification
  • 9.5.2. Next Generation Sequencing
  • 9.5.3. Polymerase Chain Reaction

10. Blood Screening Market, by Sample Type

• 10.1. Introduction
• 10.2. Plasma
• 10.3. Serum
• 10.4. Whole Blood

11. Blood Screening Market, by Testing Mode

• 11.1. Introduction
• 11.2. Lab Based
• 11.3. Point Of Care

12. Blood Screening Market, by End User

• 12.1. Introduction
• 12.2. Blood Banks
• 12.3. Hospitals & Clinics
• 12.4. Diagnostic Laboratories

13. Blood Screening Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Latin America
• 13.5. Africa
• 13.6. Middle East

14. Blood Screening Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. BRICS
• 14.4. European Union
• 14.5. ASEAN
• 14.6. GCC

15. Blood Screening Market, by Country

• 15.1. China
• 15.2. United States
• 15.3. Japan
• 15.4. India
• 15.5. Germany
• 15.6. United Kingdom
• 15.7. Australia
• 15.8. France
• 15.9. South Korea
• 15.10. Italy
• 15.11. Canada
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Agena Bioscience, Inc.
• 17.3. Becton, Dickinson and Company
• 17.4. Bio-Rad Laboratories, Inc.
• 17.5. bioMerieux SA
• 17.6. Cerus Corporation
• 17.7. Danaher Corporation
• 17.8. DiaSorin S.p.A.
• 17.9. F. Hoffmann-La Roche Ltd
• 17.10. Fresenius Kabi AG
• 17.11. Grifols, S.A.
• 17.12. Haemonetics Corporation
• 17.13. Hologic, Inc.
• 17.14. Immucor, Inc.
• 17.15. Merck KGaA
• 17.16. Ortho Clinical Diagnostics, Inc.
• 17.17. QIAGEN N.V.
• 17.18. Quotient Suisse SA
• 17.19. Revvity, Inc.
• 17.20. Siemens Healthineers AG
• 17.21. Sysmex Corporation
• 17.22. Terumo BCT, Inc.
• 17.23. Thermo Fisher Scientific Inc.
• 17.24. Trinity Biotech plc
• 17.25. Tulip Diagnostics (P) Ltd.
• 17.26. Werfen S.A.